Figure 5. lnc-LOC645166 promotes adriamycin resistance by activating GATA3. (A) A heatmap of top ADR-resistant genes. (B) Common ADR-resistant genes by microarray and GEO database were selected as potential target genes. (C) RT–qPCR analysis of GATA3 when lnc-LOC645166 was silenced or overexpressed. (D) Western blots analysis of the GATA3 when lnc-LOC645166 was silenced or overexpressed. (E) Western blots analysis of the GATA3 protein in tumors derived from adriamycin resistance and sensitive patients. R means the resistance, S means sensitive. (F) Representative immunostaining of GATA3 in an independent set of tumor samples with good or poor responses to adriamycin therapy. R means resistant to ADR therapy, S means sensitive to ADR therapy. Scale bar=100 μm (G) Representative immunostaining of GATA3 in the transplanted tumors. Scale bar=50μm. (H) Luciferase activity assay of GATA3 luciferase reporter plasmids in breast cancer cells when lnc-LOC645166 was knockdown or overexpressed. The data represented the mean±SD of three independent experiments. *P<0.05, **P<0.01, ***P<0.001.